WHO WANTS TO BE AN EYECARE MILLIONAIRE?

THE INTREPID EDITION

Thursday, November 7, 2024

6:30 PM to 7:45 PM ET

Indianapolis Artsgarden at 110 W Washington St, Indianapolis, IN 46204

Available for Live Stream

Join us for an educational and entertaining evening inspired by the popular game show format of Who Wants to be a Millionaire? During our show, attendees will participate in a dynamic, interactive learning experience where leading eyecare professionals tackle pressing issues in the field. This engaging format will involve audience participation, providing attendees a unique opportunity to test their knowledge and learn through real-time discussions and expert insights. Don’t miss this chance to enhance your clinical practice while enjoying a spirited competition among peers!

REGISTER

This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals, Inc., LENZ Therapeutics, Tarsus Pharmaceuticals, Inc., Topcon Healthcare, Inc., and Viatris, Inc.

FACULTY

Jacob Lang, OD, FAAO(Host and Program Chair)

Nathan Lighthizer, OD, FAAO

Daniel Epshtein, OD, FAAO

Carolyn Majcher, OD, FAAO

Selina McGee, OD, FAAO

Justin Schweitzer, OD, FAAO

Mark E. Schaeffer, OD, FAAO

Vin T. Dang, OD, FAAO

Damon Dierker, OD, FAAO

AGENDA & TOPICS

6:30 PM

6:40 PM

6:55 PM


7:10 PM

7:25 PM

7:40 PM

7:45 PM

Welcome and Introduction

Presbyopia

Demodex blepharitis and Neurotrophic Keratitis

Glaucoma

Retina

Summary and Closing Remarks

Conclude

LEARNING OBJECTIVES

  1. Describe the role of Demodex blepharitis and integrate treatment protocols based on the patients’ characteristics and the safety and efficacy of treatment. 

  2. Describe the pathophysiology and clinical presentation of neurotrophic keratitis and develop and implement personalized management strategies to optimize patient outcomes. 

  3. Assess the risks and benefits of current treatments for glaucoma and employ strategies to select the most appropriate treatment strategy for patients. 

  4. Describe modern screening protocols for dry AMD/GA for earlier detection and integrate the evidence-based diagnostics tools and criteria into practice. 

  5. Explain the mechanisms of action for current and emerging non-surgical treatments for presbyopia, analyze published clinical trial data, and identify ideal patient candidates for each treatment option.

  6. Integrate updated referral timing and criteria into practice.
REGISTER

This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals, Inc., LENZ Therapeutics, Tarsus Pharmaceuticals, Inc., Topcon Healthcare, Inc., and Viatris, Inc.

The Fundingsland Group (TFG) is an independent medical education company that believes in providing compelling, compliant, and effective peer-to-peer education that addresses gaps in clinical knowledge, opinions, and practice patterns. Through a unique, data-driven process, TFG identifies key educational needs and evaluates progress towards meeting clearly defined goals. By strategically collaborating with education partners and industry experts, we create customized education programs that seek to change opinions, affect practice patterns and, ultimately, improve patient care. 

© 2024 The Fundingsland Group. All rights reserved.